Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma?
Lok
A S
AS
Tulane University, New Orleans, LA, USA.
D006528:Carcinoma, Hepatocellular / Q000517:prevention & control* / Q000821:virology; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D006509:Hepatitis B / Q000150:complications / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000517:prevention & control* / Q000821:virology; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000821:virology; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins